Study of a new drug for advanced lung cancer that stopped responding to current treatments
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new medicine, STX-241, for people with a specific type of advanced lung cancer (NSCLC) that has stopped responding to current targeted therapies. The goal is to see if this new drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer (NSCLC) with a specific EGFR mutation (ex19del or L858R).
- Your cancer has progressed after treatment with a third-generation EGFR TKI (like osimertinib).
- Your tumor has a specific additional mutation (C797X) that may make it resistant to current drugs.
- You are generally in good health (able to care for yourself) and have adequate organ function.
- You have at least one measurable tumor that can be assessed by scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
This study tests a new drug called XTX501 for people with advanced non-small cell lung cancer (NSCLC) or other solid tumors. The drug may help the immune system fight cancer, and the study aims to see if it is safe and effective.
This study tests a new drug called JSKN016 in people with advanced non-small cell lung cancer whose standard treatments have stopped working. The drug may help shrink tumors or slow the cancer's growth, and the study looks at safety and effectiveness.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.